|Mr. Nicholas John Robbins-Cherry||CFO, Company Sec. & Director||298.24k||N/A||1969|
|Dr. Craig Richard Cook||CEO, COO & Director||N/A||N/A||1967|
|Mr. Rob Rainey FCA MBA MA||Head of Corp. Devel.||N/A||N/A||N/A|
|Dr. Tim Sparey Ph.D.||Chief Bus. Officer||N/A||N/A||N/A|
|Mr. Justin Barry BSc (Hons.), MBIOL, CBIOL, QP||Head of Manufacturing||N/A||N/A||N/A|
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer. Midatech Pharma PLC is collaborating with universities and pharmaceutical companies to develop its platform technologies into a range of products. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.
Midatech Pharma Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.